Aortic stenosis represents a growing health care burden in high-income countries. Currently, the only definitive treatment is surgical or transcatheter valve intervention at the end stages of disease. As the understanding of the underlying pathophysiology evolves, many promising therapies are being investigated. These seek to both slow disease progression in the valve and delay the transition from hypertrophy to heart failure in the myocardium, with the ultimate aim of avoiding the need for valve replacement in the elderly patients afflicted by this condition. Noninvasive imaging has played a pivotal role in enhancing our understanding of the complex pathophysiology underlying aortic stenosis, as well as disease progression in both the valve and myocardium. In this review, the authors discuss the means by which contemporary imaging may be used to assess disease progression and how these approaches may be utilized, both in clinical Over time, the left ventricle (LV) responds to the consequent increase in afterload by myocyte hypertrophy, extracellular expansion, and ultimately myocardial fibrosis and decompensation (4, 5) . In this review, we will discuss how these complex pathophysiological processes might be monitored with modern imaging techniques and ultimately modulated using novel therapeutic interventions.
Over time, the left ventricle (LV) responds to the consequent increase in afterload by myocyte hypertrophy, extracellular expansion, and ultimately myocardial fibrosis and decompensation (4, 5) . In this review, we will discuss how these complex pathophysiological processes might be monitored with modern imaging techniques and ultimately modulated using novel therapeutic interventions.
PATHOPHYSIOLOGY OF AS
THE VALVE. The initiation phase of AS shares many pathophysiological similarities with atherosclerosis and is dominated by inflammation, lipid infiltration, and extracellular matrix remodeling under the control of inflammatory signaling pathways (6) (7) (8) (9) (10) . Like atherosclerosis, the initiating insult appears to be a 
WHAT DO WE REQUIRE OF IMAGING IN AS?
Cardiac imaging is pivotal to the management of AS and is relied on to confirm the diagnosis and to grade stenosis severity and assess myocardial health both at baseline and over time. AS is a slowly progressive condition that advances at a variable and inconsistent rate. To accurately measure or predict disease progression over time, imaging tests must have sufficient reproducibility and robustness to detect small changes in disease severity with high accuracy. In the clinical setting, this is of utmost importance when selecting the appropriate management strategy and optimal timing of intervention for the individual patient. In the research setting, these attributes are crucial in clinical trials seeking to investigate efficacy of novel therapies. Indeed, imaging biomarkers with improved repeatability and sensitivity to change will minimize sample sizes, follow-up duration, and the expense of trials. Drug trials using imaging endpoints therefore desire biomarkers that maximize the progression-to-noise ratio: the ratio between the magnitudes of average progression in a particular parameter compared with its scan-rescan repeat- (27, 28) . However, peak velocity is dependent on flow status and accurate alignment of the echocardiography probe with the jet of blood through the valve. Whereas mean gradient is subject to the same limitations as peak velocity, AVA is in principle less flow-dependent.
However, measurements of AVA can represent an important source of discrepancy, particularly as a result of variations in direct measurements of the LV outflow tract. As LV outflow tract diameter is squared Noninvasive imaging provides the ability to directly image the aortic valve and consequent pathophysiological effects on the myocardium. Imaging the valve may be performed by computed tomography (CT) to quantify aortic valve calcification (AVC) load (CT-AVC), positron emission tomography (PET) to measure calcification activity and/or echocardiography to assess hemodynamic severity. The response of the left ventricle (LV) may be assessed by echocardiographic measures of mass, ejection fraction and/or strain, whereas cardiac magnetic resonance (CMR) offers additional quantification of fibrosis. The ability of these techniques to detect therapeutic efficacy depends on the scan-rescan repeatability of the test and the rate of change of the parameter being measured. These attributes are being exploited in a number of ongoing studies to investigate novel therapies for aortic stenosis. AS ¼ aortic stenosis; ECV ¼ extracellular volume; iECV ¼ indexed extracellular volume; LGE ¼ late gadolinium enhancement; PDE5 ¼ phosphodiesterase type 5.
Measuring Disease Progression and Assessing Novel Therapies in AS For these reasons, interest in developing novel assessments of disease severity and progression in AS is growing, and novel imaging techniques may complement echocardiography in adjudicating disease severity and monitoring disease progression.
COMPUTED TOMOGRAPHY CALCIUM SCORING
Calcification is the predominant process causing valve obstruction in AS. Quantification of the calcium burden has therefore been suggested as an alternative flow-independent method of determining disease severity (35) . This was first demonstrated using a semiquantitative assessment on echocardiography (35, 36) , although the clinical utility of this approach has been limited by subjectivity and suboptimal reproducibility (37) . Interest has instead turned to 
POSITRON EMISSION TOMOGRAPHY
Positron emission tomography (PET) is another novel technique, the use of which is being explored in AS.
By monitoring biological processes within the body, this modality has the potential to offer important mechanistic insights into pathophysiology. Furthermore, as a marker of disease activity and very early calcium formation, there is growing interest in using PET to detect early therapeutic effects in AS at a stage in the process when calcium is more likely to be reversible ( Figure 2 ).
Radiolabeled sodium fluoride ( 18 F-NaF) is a widely available PET tracer that can be used to measure calcification activity in the vasculature, with an affinity for developing microcalcification (42) (43) (44) (45) . 18 F-NaF activity is increased in patients with aortic valve disease compared with the healthy population, with a progressive rise in PET uptake with increasing severity of AS (jet velocity and calcium score) (39) .
Furthermore, early studies have suggested that 18 F-NaF activity predicts the rate of future disease progression as measured by CT-AVC and 
Measuring Disease Progression and Assessing Novel Therapies in AS echocardiography (45, 46) . Indeed, new areas of macrocalcification appear to subsequently develop at sites of increased baseline 18 F-NaF uptake, consistent with this tracer identifying developing calcification before it is visible on CT ( Figure 3) . As a marker of disease activity, 18 F-NaF therefore holds potential in detecting therapeutic effects more rapidly than conventional anatomical imaging approaches do (47) . 
ASSESSING THE MYOCARDIUM
In addition to monitoring progressive valve narrowing, noninvasive imaging may also provide detailed assessments of the LV remodeling response: from Doris et al. Doris et al.
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Indexed ECV is therefore potentially the most attractive measure for assessing myocardial fibrosis progression in AS, with further multicenter trials required for validation. Regardless of the stage of disease, it appears probable that calcification is more likely to be reversible in its earlier stages of development, meaning that imaging techniques that can identify early developing calcification, such as 18 F-NaF PET, are likely to be of value (Table 1) . 
USE OF IMAGING TO TEST DRUG EFFICACY

